找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Critical Care of COVID-19 in the Emergency Department; Joseph R. Shiber Book 2021 The Editor(s) (if applicable) and The Author(s), under e

[復(fù)制鏈接]
樓主: hormone-therapy
51#
發(fā)表于 2025-3-30 12:12:35 | 只看該作者
Point of Care Echocardiography in the COVID-19 Patient,ritically ill COVID-19 patient, facilitating early implementation of definitive therapy for a multitude of conditions associated with COVID-19 infection including thromboembolic disease, pleural effusion, pulmonary edema, and myocarditis. Through a protocolized approach to cleaning and disinfection,
52#
發(fā)表于 2025-3-30 14:52:05 | 只看該作者
Inter-Hospital Transfer of the Critically Ill COVID-19 Patient,tinued management of these patients may exceed the capacity or capability of the hospital to which the patient presented. Inter-facility transfer of a critically ill patient with COVID-19 may therefore be necessary. Multiple models for transfer of pediatric, ST-elevation myocardial infarction, and t
53#
發(fā)表于 2025-3-30 19:28:38 | 只看該作者
54#
發(fā)表于 2025-3-30 22:06:43 | 只看該作者
55#
發(fā)表于 2025-3-31 02:17:58 | 只看該作者
Management of Undifferentiated Critically Ill COVID-19 Patients,lly ill COVID-19 patients’ airway, breathing, and circulations (ABCs) is still paramount. This chapter reported recommendations from current literature regarding managing the undifferentiated critically ill COVID-19 patients. We also summarized our current knowledge regarding treatment for COVID-19.
56#
發(fā)表于 2025-3-31 06:03:47 | 只看該作者
57#
發(fā)表于 2025-3-31 11:25:27 | 只看該作者
58#
發(fā)表于 2025-3-31 14:07:02 | 只看該作者
Pharmacological Agents for COVID-19 Patients,entation. Current evidence will support corticosteroids, thromboprophylaxis, and remdesivir. Limited evidence exists around the monoclonal antibodies, at this time. Some treatment options are to be initiated earlier and in higher-risk patient populations to reduce progression to more severe disease and hospitalization.
59#
發(fā)表于 2025-3-31 19:22:13 | 只看該作者
60#
發(fā)表于 2025-4-1 00:05:32 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-9 09:30
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
萍乡市| 夏河县| 宝兴县| 大同市| 息烽县| 永州市| 淳安县| 建瓯市| 铁岭县| 财经| 惠水县| 桂平市| 江阴市| 克什克腾旗| 元江| 兴义市| 肇庆市| 闻喜县| 仁寿县| 曲沃县| 湘潭县| 讷河市| 丹凤县| 连城县| 淮阳县| 平顺县| 黔西县| 大化| 安陆市| 夹江县| 辽中县| 永仁县| 清徐县| 陆丰市| 日土县| 高平市| 建宁县| 蒙自县| 乡宁县| 新竹市| 五莲县|